Skip to main content
UniHealth

Doctor search

Matthew Thomas Wheeler, MD

Cardiovascular Disease (Cardiology) · Stanford

NPI 1144428392

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Offices
4

Offices

4 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Mills-Peninsula Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wheeler’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A98583 · Current

Licensed to practise in California · since 2007 · expires 2026-12-31 · University of Chicago, Pritzker School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Peninsula Medical Center
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.139BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.242BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.21 (0.27 to 2.15) · 1,258 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.81 (0.51 to 1.1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths155.44 (112.67 to 198.21) · 90 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.5 · 32 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 82 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 188 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9 · 473 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.8 · 342 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.4 · 485 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 3,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.4) · 6,904 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,052 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.41 (1.43 to 5.39) · 1,695 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.72 (0.17 to 3.28) · 665 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.66 to 3.56) · 1,545 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.1 (1.3 to 12.9) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.96 (2.63 to 9.29) · 653 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.15 to 3.08) · 418 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.14 (0 to 0.78) · 5,539 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 192 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.215No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.263No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.74No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.3 · 300 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19 · 702 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits1.2 · 207 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13.6 · 531 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits24.3 · 343 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.1 · 449 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.5 (2.8 to 7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.6 (6.7 to 13.7) · 85 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.7 · 189 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11 · 45 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 117 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (9.7 to 17.2) · 584 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.2) · 764 casesNo differentJan 2024 – Dec 2024

What patients said (523 patients answered, 27% of those asked)

Patient survey stars by topic at Peninsula Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Peninsula Medical Center
Room was "always" clean76%
Nurses "always" communicated well81%
Doctors "always" communicated well80%
Staff "always" explained58%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$29,572

Medicare paid this office $29,572 for 575 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$3,939$106
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only402$3,187$7
Long return visit (40+ min)22$2,998$130
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$2,478$71
Initial hospital care with moderate level of medical decision making at least 75 minutes13$1,919$148
See all 12 services
Every Original Medicare service billed
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$3,939$106
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only402$3,187$7
Long return visit (40+ min)22$2,998$130
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$2,478$71
Initial hospital care with moderate level of medical decision making at least 75 minutes13$1,919$148
Return visit (30+ min)13$1,539$118
Return visit (30+ min)18$1,398$78
Hospital discharge day management, 30 minutes or less17$1,341$74
Test for exercise-induced heart and lung stress23$1,319$57
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days15$1,193$31
Office for the evaluation and management of established patient that may not require presence of healthcare professional28$911$23
Heart rhythm review and interpretation of continous external ekg over 8-15 days25$570$23

Who their Medicare patients are

575 Original Medicare patients in 2024. Average age 74 · Under 65 11% · 85 and older 16% · Women 52% · Also on Medicaid 30% · Health risk score 2.26. Above the middle of the specialty; the typical cardiology clinician is at 1.71.

Conditions among them: High blood pressure 75% · Heart failure 52% · Coronary heart disease 49% · Atrial fibrillation 46% · Chronic kidney disease 45% · Diabetes 41% · Depression 27% · Cancer 24% · COPD 21% · Dementia 18% · Stroke 18%.

The office billed $157,254, Medicare allowed $37,983 and paid $29,572; for 817 services of 29 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024575817742.26$157,254$29,572
2023363780722.42$196,504$43,963
2022228729692.53$221,099$47,234
2021220578692.39$167,114$35,156
2020249731682.39$197,954$41,331
20194821,054712.35$210,021$47,625
2018478977712.09$197,936$46,890
2017349903702.40$200,116$45,401
2016125708672.44$214,820$48,833
2015127650662.46$180,491$44,801
201489466652.05$124,444$33,357
201355239692.59$65,973$15,179

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 13 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes59$14,675$72
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes26$7,240$110
Long return visit (40+ min)24$3,325$128
Return visit (30+ min)24$2,470$88
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,121$152
Hospital discharge day management, 30 minutes or less25$1,938$75
Evaluation of lower heart chamber assist device14$1,567$36
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only179$1,503$7
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,315$120
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes13$1,310$44
Test for exercise-induced heart and lung stress17$985$58
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days14$826$31
Heart rhythm review and interpretation of continous external ekg over 8-15 days20$407$20

2022: 8 services

Original Medicare services billed in 2022
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$15,281$94
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes39$12,038$65
Long return visit (40+ min)29$4,041$122
Return visit (30+ min)28$2,552$82
Heart rhythm review and interpretation of continous external ekg over 8-15 days71$1,796$25
Test for exercise-induced heart and lung stress11$696$63
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days13$517$29
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only37$266$7

2021: 9 services

Original Medicare services billed in 2021
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$11,455$95
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes30$6,971$66
Long return visit (40+ min)30$3,774$126
Return visit (30+ min)32$3,105$91
Test for exercise-induced heart and lung stress13$833$64
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only88$817$8
Hospital discharge day management, 30 minutes or less12$815$68
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days12$703$31
Heart rhythm review and interpretation of continous external ekg over 8-15 days20$554$24

2020: 10 services

Original Medicare services billed in 2020
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$12,662$94
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes31$8,098$65
Evaluation of lower heart chamber assist device30$5,038$39
Return visit (30+ min)40$3,004$68
Long return visit (40+ min)23$1,971$82
Hospital discharge day management, 30 minutes or less14$1,177$69
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only105$941$8
Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days13$686$30
Review and interpretation of external ekg recording for more than 48 hours up to 21 days29$641$21
Short return visit (20+ min)11$526$48

2019: 11 services

Original Medicare services billed in 2019
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$14,907$94
Evaluation of lower heart chamber assist device34$7,336$41
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes30$5,479$66
Return visit (30+ min)50$3,475$68
Long return visit (40+ min)31$3,239$95
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only342$2,928$8
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,299$177
Hospital discharge day management, 30 minutes or less16$1,351$68
Programming of multiple lead implantable defibrillator system13$675$52
Programming of dual lead implantable defibrillator system12$669$51
Review and interpretation of external ekg recording for more than 48 hours up to 21 days27$662$25

2018: 10 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$17,226$94
Evaluation of lower heart chamber assist device31$5,569$40
Long return visit (40+ min)45$5,133$92
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,911$182
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only316$2,624$8
Return visit (30+ min)31$2,268$65
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,242$65
Hospital discharge day management, 30 minutes or less16$1,203$67
Review and interpretation of external ekg recording for more than 48 hours up to 21 days45$1,095$24
Programming of dual lead implantable defibrillator system12$633$53

2017: 8 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$16,359$93
Evaluation of lower heart chamber assist device39$8,264$41
Long return visit (40+ min)49$5,748$99
Return visit (30+ min)48$3,245$59
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,175$181
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only229$2,078$8
Hospital discharge day management, 30 minutes or less12$840$65
Review and interpretation of external ekg recording for more than 48 hours up to 21 days24$612$24

2016: 7 services

Original Medicare services billed in 2016
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$17,407$92
Evaluation of lower heart chamber assist device30$10,440$40
Long return visit (40+ min)53$6,077$96
Return visit (30+ min)33$2,414$64
Hospital discharge day management, 30 minutes or less14$920$61
Test for exercise-induced heart and lung stress12$747$62
Evaluation of single, dual, or multiple lead implantable defibrillator system16$702$41

2015: 7 services

Original Medicare services billed in 2015
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$14,970$91
Evaluation of lower heart chamber assist device40$9,017$40
Long return visit (40+ min)59$7,824$95
Return visit (30+ min)42$3,532$65
Hospital discharge day management, 30 minutes or less11$728$66
Evaluation of single, dual, or multiple lead implantable defibrillator system14$661$41
Programming of dual lead implantable defibrillator system11$575$52

2014: 7 services

Original Medicare services billed in 2014
Long return visit (40+ min)58$9,309$94
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$7,671$92
Evaluation of lower heart chamber assist device26$5,242$40
Return visit (30+ min)36$3,268$67
New patient visit (60+ min)12$1,795$150
Test for exercise-induced heart and lung stress13$872$62
Evaluation of single, dual, or multiple lead implantable defibrillator system11$453$41

2013: 4 services

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$3,352$62
Evaluation of lower heart chamber assist device15$3,082$39
Return visit (30+ min)21$1,792$66
Long return visit (40+ min)11$1,049$95

Medicaid work

$3,075 in 2024

Medicaid paid $3,075 for 335 billed services this clinician did in 2024, up to 99 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only335$3,075
Medicaid work by year
2024335199$3,075
2023236291$4,105
202244229$752
202167162$538
202092170$881
2019217153$2,185
2018177170$1,753
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES57$2,591
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only179$1,514

2022

Largest Medicaid services in 2022
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only31$381
Long return visit (40+ min)13$371

2021

Largest Medicaid services in 2021
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only67$538

2020

Largest Medicaid services in 2020
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only92$881

2019

Largest Medicaid services in 2019
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only217$2,185

2018

Largest Medicaid services in 2018
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only177$1,753

Drugs they prescribed that Part D paid

$837,334

Pharmacies billed $837,334 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,051) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.

766 generic and fewer than 11 brand-name prescriptions · $837,334 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Camzyos41$374,551$9,135
Eliquis83$80,049$964
Entresto58$71,220$1,228
Repatha Sureclick25$20,180$807
Jardiance18$19,058$1,059
See all 28 drugs
Every Part D drug this clinician prescribed
Camzyos41$374,551$9,135
Eliquis83$80,049$964
Entresto58$71,220$1,228
Repatha Sureclick25$20,180$807
Jardiance18$19,058$1,059
Farxiga13$11,795$907
Xarelto13$8,128$625
Dofetilide12$4,041$337
Sirolimus14$2,894$207
Tacrolimus15$1,471$98
Eplerenone13$1,126$87
Metoprolol33$743$23
Ezetimibe20$675$34
Rosuvastatin70$627$9
Pravastatin41$572$14
Spironolactone59$545$9
Losartan52$460$9
Amlodipine Besylate44$379$9
Carvedilol51$356$7
Atorvastatin28$204$7
Pantoprazole20$200$10
Metoprolol16$138$9
Hydralazine20$117$6
Lisinopril41$109$3
Tamsulosin14$102$7
Levothyroxine15$73$5
Prednisone12$66$6
Furosemide24$45$2

Year by year

Part D prescribing by year
20241,0511390% (0)None$837,334
20231,3551960% (0)None$420,954
20221,4811860% (0)17%$343,759
20211,342199None12%$239,829
20201,527193NoneNone$271,716
20199391610% (0)16%$122,461
2018829116None17%$87,791
2017699106None25%$65,842
201656494None24%$33,785
201557677NoneNone$41,786
201445265None20%$29,956
2013117300% (0)22%$8,532

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 37 drugs

Part D drugs prescribed in 2023
Camzyos20$179,326$8,966
Eliquis67$69,400$1,036
Entresto34$34,233$1,007
Everolimus17$25,819$1,519
Farxiga20$24,615$1,231
Sirolimus37$13,910$376
Xarelto12$7,005$584
Tacrolimus42$5,301$126
Rosuvastatin127$3,818$30
Mycophenolic Acid12$3,621$302
Eplerenone23$3,416$149
Mycophenolate Mofetil16$1,777$111
Metoprolol53$1,525$29
Carvedilol57$1,195$21
Diltiazem 24hr Er (Cd)17$973$57
Atorvastatin45$899$20
Losartan65$837$13
Potassium Chloride17$792$47
Lisinopril55$700$13
Bumetanide22$677$31
Amlodipine Besylate52$668$13
Verapamil Er12$617$51
Clonidine12$485$40
Spironolactone34$432$13
Levothyroxine26$412$16
Pantoprazole29$355$12
Ezetimibe17$308$18
Hydralazine17$300$18
Famotidine19$258$14
Hydrochlorothiazide24$211$9
Tamsulosin17$165$10
Metoprolol11$161$15
Trazodone11$155$14
Furosemide30$146$5
Prednisone15$131$9
Clonidine19$120$6
Pravastatin17$104$6

2022: 39 drugs

Part D drugs prescribed in 2022
Eliquis75$74,727$996
Entresto62$56,705$915
Envarsus Xr11$23,405$2,128
Sirolimus28$18,617$665
Farxiga17$16,002$941
Repatha Sureclick14$8,803$629
Tacrolimus66$6,207$94
Mycophenolic Acid14$5,664$405
Eplerenone27$5,463$202
Rosuvastatin108$4,871$45
Cyclosporine Modified17$3,173$187
Diltiazem 24hr Er (Cd)33$2,164$66
Metoprolol61$1,804$30
Mycophenolate Mofetil14$1,729$123
Losartan67$1,084$16
Clonidine11$1,074$98
Carvedilol70$948$14
Potassium Chloride15$759$51
Ezetimibe21$748$36
Spironolactone48$675$14
Amlodipine Besylate67$545$8
Pantoprazole59$499$8
Verapamil Er11$488$44
Atorvastatin53$471$9
Hydralazine44$425$10
Lisinopril49$352$7
Levothyroxine26$336$13
Famotidine22$320$15
Warfarin20$290$15
Bumetanide12$240$20
Furosemide29$224$8
Acyclovir18$203$11
Hydrochlorothiazide18$171$9
Sulfamethoxazole-Trimethoprim17$162$10
Tamsulosin13$161$12
Metoprolol12$124$10
Gabapentin15$88$6
Allopurinol14$77$5
Prednisone15$63$4

2021: 40 drugs

Part D drugs prescribed in 2021
Eliquis45$49,565$1,101
Entresto37$37,952$1,026
Atovaquone13$13,077$1,006
Tacrolimus71$8,664$122
Xarelto15$8,592$573
Sirolimus23$8,385$365
Eplerenone31$6,109$197
Rosuvastatin64$2,363$37
Cinacalcet12$1,870$156
Metoprolol75$1,745$23
Diltiazem 24hr Er (Cd)24$1,713$71
Mycophenolate Mofetil22$1,526$69
Valganciclovir13$1,275$98
Bumetanide12$1,179$98
Carvedilol65$917$14
Ezetimibe20$901$45
Potassium Chloride13$894$69
Losartan66$832$13
Pantoprazole29$750$26
Spironolactone44$716$16
Atorvastatin45$660$15
Omega-3 Acid Ethyl Esters12$587$49
Pravastatin34$570$17
Acyclovir19$447$24
Amlodipine Besylate53$421$8
Isosorbide Mononitrate Er31$384$12
Hydralazine20$381$19
Ramipril11$285$26
Lisinopril41$265$6
Gabapentin17$247$15
Metoprolol15$213$14
Hydrochlorothiazide22$194$9
Sertraline18$181$10
Warfarin15$174$12
Tamsulosin16$163$10
Furosemide21$152$7
Triamterene-Hydrochlorothiazid11$114$10
Famotidine11$103$9
Mirtazapine15$97$6
Prednisone13$74$6

2020: 36 drugs

Part D drugs prescribed in 2020
Cresemba12$64,199$5,350
Eliquis33$33,288$1,009
Entresto18$19,719$1,095
Sirolimus60$19,627$327
Tacrolimus106$14,527$137
Eplerenone31$5,553$179
Myrbetriq12$4,983$415
Rosuvastatin77$4,280$56
Diltiazem 24hr Er (Cd)13$2,430$187
Ezetimibe20$2,130$107
Bumetanide40$1,984$50
Metoprolol80$1,703$21
Mycophenolate Mofetil16$1,669$104
Potassium Chloride25$1,440$58
Atorvastatin44$1,071$24
Carvedilol58$831$14
Pantoprazole40$704$18
Hydralazine47$642$14
Losartan52$590$11
Gabapentin37$556$15
Amiodarone11$529$48
Spironolactone54$522$10
Pravastatin34$414$12
Isosorbide Mononitrate Er21$400$19
Lisinopril46$346$8
Warfarin27$307$11
Amlodipine Besylate54$284$5
Levothyroxine12$261$22
Tamsulosin14$232$17
Hydrochlorothiazide31$229$7
Famotidine14$213$15
Furosemide33$187$6
Sertraline33$162$5
Prednisone17$149$9
Levetiracetam11$46$4
Benazepril12$32$3

2019: 26 drugs

Part D drugs prescribed in 2019
Eliquis21$22,900$1,090
Xarelto15$12,819$855
Entresto11$7,927$721
Sirolimus21$5,813$277
Eplerenone23$4,715$205
Rosuvastatin36$2,466$68
Diltiazem 24hr Er (Cd)26$2,174$84
Metoprolol61$1,795$29
Atorvastatin54$1,288$24
Ezetimibe17$1,280$75
Bumetanide19$911$48
Gabapentin15$821$55
Spironolactone58$693$12
Carvedilol41$537$13
Losartan48$453$9
Potassium Chloride13$441$34
Warfarin38$431$11
Pantoprazole23$269$12
Lisinopril36$240$7
Amlodipine Besylate32$238$7
Furosemide35$218$6
Hydrochlorothiazide24$185$8
Hydralazine16$177$11
Sertraline26$161$6
Benazepril13$65$5
Levetiracetam12$60$5

2018: 23 drugs

Part D drugs prescribed in 2018
Eliquis15$16,064$1,071
Xarelto20$13,266$663
Multaq11$7,087$644
Disopyramide Phosphate18$4,534$252
Metoprolol90$3,430$38
Verapamil13$2,517$194
Ezetimibe13$1,428$110
Mycophenolate Mofetil14$1,386$99
Rosuvastatin18$1,001$56
Bumetanide17$720$42
Atorvastatin31$570$18
Spironolactone28$542$19
Losartan54$420$8
Carvedilol37$376$10
Warfarin38$375$10
Furosemide37$308$8
Lisinopril24$281$12
Hydrochlorothiazide33$191$6
Pantoprazole23$156$7
Amlodipine Besylate29$140$5
Sertraline18$132$7
Isosorbide Mononitrate Er11$103$9
Metoprolol12$51$4

2017: 17 drugs

Part D drugs prescribed in 2017
Xarelto15$12,024$802
Eliquis14$7,496$535
Metoprolol87$3,074$35
Verapamil11$2,107$192
Rosuvastatin16$1,253$78
Potassium Chloride20$702$35
Atorvastatin27$487$18
Warfarin29$471$16
Levothyroxine25$367$15
Losartan40$330$8
Spironolactone27$313$12
Hydrochlorothiazide53$311$6
Furosemide32$258$8
Carvedilol32$252$8
Verapamil Er11$143$13
Lisinopril24$141$6
Metoprolol16$68$4

2016: 14 drugs

Part D drugs prescribed in 2016
Eliquis11$3,706$337
Metoprolol73$2,601$36
Verapamil Er11$770$70
Potassium Chloride28$759$27
Spironolactone42$545$13
Warfarin22$326$15
Furosemide54$310$6
Carvedilol27$298$11
Atorvastatin17$278$16
Gabapentin15$269$18
Lisinopril37$226$6
Losartan21$143$7
Hydrochlorothiazide19$117$6
Amlodipine Besylate16$114$7

2015: 15 drugs

Part D drugs prescribed in 2015
Pradaxa12$5,243$437
Metoprolol57$2,106$37
Amiodarone17$1,509$89
Disopyramide Phosphate11$1,150$105
Methotrexate13$788$61
Verapamil Er25$633$25
Spironolactone37$443$12
Atorvastatin27$286$11
Potassium Chloride12$281$23
Lisinopril51$269$5
Carvedilol18$223$12
Furosemide43$220$5
Losartan33$197$6
Hydrochlorothiazide29$141$5
Metoprolol24$124$5

2014: 11 drugs

Part D drugs prescribed in 2014
Metoprolol52$2,799$54
Spironolactone43$552$13
Amiodarone17$249$15
Verapamil Er13$234$18
Clopidogrel17$227$13
Carvedilol12$226$19
Lisinopril32$220$7
Metoprolol13$130$10
Atorvastatin14$127$9
Hydrochlorothiazide23$111$5
Furosemide20$99$5

2013: 1 drug

Part D drugs prescribed in 2013
Lisinopril12$136$11

Money from drug and device companies

$48 in 2024

Industry payments by year
202411None$48
202211None$125

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
KerecisKerecis Omega3 Surgiclose$48
1 payment
  • Meals for Kerecis Omega3 Surgiclose · 2024-01-11 · $48
See the published payment
Every published payment
KerecisMeals · 2024-01-11Kerecis Omega3 Surgiclose$48
See earlier years (2022)

2022: $125

Payments by company in 2022
E.R. Squibb & Sons L.L.C.None$125
1 payment
  • Meals · 2022-06-07 · $125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed Maverick-Hcm Or Explorer-Hcm · 2021Their institution$169,679
E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy · 2021Their institution$122,473
E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed Maverick-Hcm Or Explorer-Hcm · 2022Their institution$112,698
E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trails (Mava-Lte) · 2023Their institution$102,455
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Mavacamten in Adults With Symptomatic Obstructive Hcm Who Are Eligible for Septal Reduction Therapy (Valor-Hcm) · 2023Their institution$75,580
E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trails (Mava-Lte) · 2025Their institution$72,051
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Mavacamten in Adults With Symptomatic Obstructive Hcm Who Are Eligible for Septal Reduction Therapy (Valor-Hcm) · 2022Their institution$60,372
Alexion Pharmaceuticals, Inc. · A Study About the Natural History in Adults With Bag3 Dilated Cardiomyopathy (A Type of Heart Disease) (Bag3 Dcm) · 2024Their institution$49,663
Amgen Inc. · Galactic-Hf · 2019Their institution$47,270
E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trails (Mava-Lte) · 2024Their institution$46,989
E.R. Squibb & Sons, L.L.C. · A Prospective Registry Study To Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive Hcm) · 2024Their institution$46,055
E.R. Squibb & Sons, L.L.C. · A Prospective Registry Study To Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-Hcm) (Discover-Hcm) · 2025Their institution$38,745
E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2024Their institution$38,545
E.R. Squibb & Sons, L.L.C. · A Study To Evaluate Mavacamten in Adults With Symptomatic Obstructive Hcm Who Are Eligible for Septal Reduction Therapy (Valor-Hcm) · 2024Their institution$36,759
Alexion Pharmaceuticals, Inc. · A Prospective Multinational Study of the Natural History of Participants With Bag3 Mutation Associated Dilated Cardiomyopathy · 2025Their institution$23,997
ARRAY BIOPHARMA INC · A Phase 3 Multinational Randomized Placebocontrolled Study of Arry371797 Pf07265803 in Patients With Symptomatic Dilated Cardiomyopathy Due To A Lamin Ac Gene Mutation · 2021Their institution$23,796
Amgen Inc. · Galactic - Hf · 2020Their institution$12,324
Array BioPharma Inc. · A Phase 3, Multinational, Randomized, Placebo-Controlled Study of Arry-371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due To A Lamin A/C Gene Mutation · 2019Their institution$12,085
Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Placebo-Controlled Patient and Investigator-Blinded Study To Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-Obstructive Hypertrophic Cardiomyopathy (Nhcm) · 2022Their institution$11,797
Alexion Pharmaceuticals, Inc. · A Study About the Natural History in Adults With Bag3 Dilated Cardiomyopathy (A Type of Heart Disease) (Bag3 Dcm) · 2025Their institution$11,403
PFIZER INC. · A Prospective Multinational Study of the Natural History of Participants With Bag3 Mutation Associated Dilated Cardiomyopathy · 2024Their institution$10,724
Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Placebo-Controlled Patient and Investigator-Blinded Study To Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-Obstructive Hypertrophic Cardiomyopathy (Nhcm) · 2020Their institution$7,627
E.R. Squibb & Sons, L.L.C. · Nhcm Phase III - A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2023Their institution$5,520
ARRAY BIOPHARMA INC · A Phase 3 Multinational Randomized Placebocontrolled Study of Arry371797 Pf07265803 in Patients With Symptomatic Dilated Cardiomyopathy Due To A Lamin Ac Gene Mutation · 2023Their institution$5,484
E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2025Their institution$3,500
Amgen Inc. · Galactic - Hf · 2021Their institution$3,140
Novartis Pharmaceuticals Corporation · A Multi-Center, Randomized, Placebo-Controlled Patient and Investigator-Blinded Study To Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-Obstructive Hypertrophic Cardiomyopathy (Nhcm) · 2021Their institution$1,907
PFIZER INC. · Pf07265803 Clinical Publication Program · 2021This clinician$1,900
E.R. Squibb & Sons, L.L.C. · A Prospective Registry Study To Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive Hcm) · 2023Their institution$1,443
PFIZER INC. · Pf07265803 Clinical Publication Program · 2022This clinician$1,400
ARRAY BIOPHARMA INC · A Phase 3 Multinational Randomized Placebocontrolled Study of Arry371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due To A Lamin Ac Gene Mutation · 2020Their institution$1,043
E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2023Their institution$135

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1144428392
Licence
CA A98583California A98583: Current · expires 2026-12-31
Trained
University of Chicago, Pritzker School of Medicine, 2005
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RA0001X (207RA0001X); Cardiology (207RC0000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-07-10
NPI last updated
2024-04-26
NPI record certified
2024-04-26

This is when the NPI record was last certified, not a medical board exam.